NVAX - Novavax, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$18.00
DETAILS
HIGH:
$25.00
LOW:
$11.00
MEDIAN:
$18.00
CONSENSUS:
$18.00
UPSIDE:
95.44%
AlphaVal
Deterministic, archetype-aware fair value
High-Growth Software
80% confidence
Primary model: Revenue × Terminal Margin DCF
Adjust Assumptions
30.0%
28.0%
12.0%
Key Value Driver
Revenue growth (30%) × margin expansion to 28%
Terminal Value % of EV
69%
Implied Market Multiple
0.9x
Plain-Language Summary
Projecting 30% revenue growth with FCF margins expanding from 0% to 28% over 10 years, discounted at 12%, the base-case value is $70.37 per share.
Analyst Consensus (External Reference)
Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.
Average Target (23 analysts)
$18.00
Analyst Range
$11.00 – $25.00
Divergence from AlphaVal
291%
Warnings
Our estimate assumes profit margins grow from 0% to 28% over 10 years. If that improvement stalls, the company is worth considerably less.
Gross margin of 94% means each dollar of revenue is highly profitable. As the company grows, overhead costs should shrink as a share of revenue, boosting overall profits.
Wall Street's average price target is $18.00 (from 23 analysts). Our estimate is 291% above the consensus -- consider that gap carefully.
Key Risks
- Current FCF misleads — the model values future margins, not today's cash
- SBC dilution is the hidden tax: 2-4% annual share growth compounds fast
- Revenue deceleration is inevitable — the question is when and how steep